CCR5 Antibody (CTC5) [Unconjugated]

Human peripheral blood lymphocytes were stained with (A) Mouse Anti-Human CCR5 Monoclonal Antibody (Catalog # MAB1802) or (B) control antibody (Catalog # MAB002), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B) and Mouse anti-Human CD3 APC-conjugated monoclonal antibody (Catalog # FAB100A). View our protocol for Staining Membrane-associated Proteins.

TGF-beta signaling regulated the expression of CCR5(A) 3×105 MDA-MB-231 and MCF-7 cells were stimulated with 1-5ng/ml TGF-beta 1 for 24 h, and total RNA was isolated and tested for CCR5 mRNA by quantitative PCR. (B) Western blot for CCR5 protein in breast cancer cells (106) under TGF-beta 1 stimulation for 48 h. Data presented were representatives of at least three independent experiments. (C) MDA-MB-231 and MCF-7 cells (3×105) were co-transfected with pGL3-CCR5 and pRL-TK and exposed to different concentrations of TGF-beta 1 for 24 h, and luciferase activities were determined. (D) MDA-MB-231 and MCF-7 cells were pre-treated with 5μM SIS3 for 2 h, and cells were subjected to luciferase assay. (E) 106 MCF-7 cells were transfected with TGF beta RI/ALK5 siRNA, and were then co-cultured with lactate-activated THP-1 macrophages (ratio 1:1) for 24 h. The protein levels of CCR5 were assayed by western blot. (F) The expression of TGF-beta 1, CCL5 and CCR5 in clinical samples obtained from breast cancer patients. The mRNA levels were measured by quantitative PCR, and the correlation between TGF-beta 1 and CCL5-CCR5 axis was shown. (G) Representative IHC staining for TGF-beta 1, CCL5 and CCR5 in breast cancer samples. The sample used was derived from 28 breast cancer cases. Scale bars represent 50 μm. *, P<0.05; **, P<0.01. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22786), licensed under a CC-BY license. Not internally tested by R&D Systems.

CCL5-CCR5 axis induced aerobic glycolysis by regulation of AMPK signaling(A) Western blot for AMPK, c-Myc, HIF-1 alpha and Akt in breast cancer cells co-cultured with 15mM lactic acid-activated THP-1 macrophages (ratio 1:1) for 72 h. Results presented were representatives of at least three independent experiments. (B) The expression of AMPK downstream signaling target ACC in breast cancer cells co-cultured as in (A). (C) MDA-MB-231 and MCF-7 cells were transfected with 50 nM AMPK alpha 1 siRNA, or pretreated with 10μM compound C for 4 h, and then incubated with 15mM lactic acid-activated THP-1 macrophages (ratio 1:1) for 48 h. The glucose uptake, lactic acid production and ATP levels were detected. (D) The inhibition of AMPK abrogated macrophage-induced EMT in MCF-7 cells. Cells were treated as described in (C). After co-culture, the expression of EMT markers, E-cadherin and vimentin, was measured by western blot. (E) Recombinant human CCL5 induced the phosphorylation of AMPK in MDA-MB-231 and MCF-7/CCR5 cells. 106 cells were treated with 50ng/ml CCL5 for defferent time points as indicated, and phosphorylated AMPK and total AMPK were investigated by western blot. (F) Inhibition of CCR5 in MDA-MB-231 cells significantly attenuated macrophage-induced AMPK phosphorylation. MDA-MB-231 cells were transfected with shRNAs designed against CCR5, or pre-treated with 5μM Maraviroc for 2 h, then co-cultured with 15 mM lactate-activated macrophages as described in (A). After co-culture, the phosphorylation of AMPK was detected by western blot. (G) Expressions of CCL5, CCR5 and p-AMPK in samples obtained from breast cancer patients (n =28). Scale bars represent 50 μm. *, P<0.05; **, P<0.01. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22786), licensed under a CC-BY license. Not internally tested by R&D Systems.

Lactate-activated macrophages induced EMT in breast cancer cells through CCL5-CCR5 axis(A) 106 THP-1 macrophages were treated with 15 mM lactate for 72 h, and then cells were washed twice and fresh media were added. Macrophages were cultured for another 24 h and the conditional media (lactate CM) was collected. The effect of CM on breast cancer cell migration was measured by double chamber transwell assay. 5μg/ml anti-CCL5 neutralizing antibody significantly decreased lactate CM-induced cell migration. (B) 106 MCF-7 cells were co-cultured with 15 mM lactate-activated macrophages in the presence of 5μg/ml anti-CCL5 antibody or not, and protein levels of EMT markers were tested by western blot. (C) 106 breast cancer cells were co-cultured with 106 lactate-activated THP-1 macrophages (or 106 lactate-activated primary macrophages) for different time points, and the expression of CCR5 was monitored by western blot. (D) MDA-MB-231 and MCF-7 cells were transfected with shCCR5 plasmids, or pre-treated with 5μM Maraviroc for 2 h, then cell migration induced by lactate CM was detected by double chamber transwell assay. Lactate CM was described in (A). (E) MCF-7 cells (106) were transfected with pcDNA3.1-CCR5, and then cultured with 10ng/ml CCL5 for 24 h. The expression of E-cadherin, N-cadherin and vimentin was investigated by western blot. (F) 106 Human primary macrophages (No. 4 and No. 9) were treated with 15 mM lactate for 72 h and CM was collected as described in (A). The migration of MDA-MB-231 cells was measured in the presence of primary macrophage CM. 5μg/ml anti-CCL5 neutralizing antibody, shRNAs designed against CCR5, or 5μM Maraviroc, significantly reduced primary macrophage CM-induced cell migration. *, P<0.05; **, P<0.01. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22786), licensed under a CC-BY license. Not internally tested by R&D Systems.

Macrophages promoted breast cancer metastasis through CCL5(A) MDA-MB-231 cells were co-cultured with 15 mM lactate-activated THP-1 macrophages for 7 days, in the presence of 5μg/ml anti-CCL5 neutralizing antibody or not. MDA-MB-231 cells were then collected and injected into the tail vein of nude mice. After two weeks, animals were sacrificed and metastatic nodules on lung surfaces were counted. (B) CCR5, HK2 and p-AMPK were immunostained in MDA-MB-231 metastases. Scale bars represent 50 μm. *, P<0.05; **, P<0.01. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22786), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, Flow, CyTOF-ready
• Clone: CTC5
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

CCR5 Antibody (CTC5) [Unconjugated] Summary

• Immunogen: CHO Chinese hamster ovary cell line transfected with human CCR5
• Specificity: Detects human CCR5 in Western blots. For additional information regarding epitope specificity for this antibody and other R&D Systems anti‑human CCR5 antibodies, see Reference 1.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CCR5
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Western Blot

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCR5 Antibody (CTC5) [Unconjugated]

• C-C CKR-5
• C-C motif chemokine receptor 5 A159A
• CCCKR5
• CC-CKR-5FLJ78003
• CCR5
• CCR-5
• CD195 antigen
• CD195
• chemokine (C-C motif) receptor 5
• chemokine receptor CCR5
• chemr13
• CKR5
• CKR-5
• HIV-1 fusion coreceptor
• IDDM22CMKBR5C-C chemokine receptor type 5

Background

CCR5 is a G protein-linked seven transmembrane domain chemokine receptor. CCR5 serves as a receptor for several chemokines including MIP-1 alpha , MIP-1 beta , MCP-2, and RANTES. It also functions as a coreceptor for Macrophage Tropic HIV-1 infection.

1. Lee, B. et al. (1999) J. Biol. Chem. 274:9617.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCR5 Antibody (MAB1802)(10)

Publications using MAB1802

• H Branscome, P Khatkar, S Al Sharif, D Yin, S Jacob, M Cowen, Y Kim, J Erickson, CA Brantner, N El-Hage, LA Liotta, F Kashanchi Retroviral infection of human neurospheres and use of stem Cell EVs to repair cellular damage Scientific Reports, 2022-02-07;12(1):2019. 2022-02-07 [PMID: 35132117] (Western Blot, Human)
• M Weichseldo, Y Tagaya, M Reitz, AL DeVico, OS Latinovic Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies Journal of Translational Medicine, 2022-01-24;20(1):39. 2022-01-24 [PMID: 35073923] (ICC, Human)
• C Jacquemard, F Koensgen, P Colin, B Lagane, E Kellenberg Modeling of CCR5 Recognition by HIV-1 gp120: How the Viral Protein Exploits the Conformational Plasticity of the Coreceptor Viruses, 2021-07-18;13(7):. 2021-07-18 [PMID: 34372601] (Flow Cytometry, Human)
• P Colin, Z Zhou, I Staropoli, J Garcia-Per, R Gasser, M Armani-Tou, Y Benureau, N Gonzalez, J Jin, BJ Connell, S Raymond, P Delobel, J Izopet, H Lortat-Jac, J Alcami, F Arenzana-S, A Brelot, B Lagane CCR5 structural plasticity shapes HIV-1 phenotypic properties PLoS Pathog., 2018-12-06;14(12):e1007432. 2018-12-06 [PMID: 30521629] (Competitive Binding Assay, Human)
• Sensen Lin, Li Sun, Xiaodan Lyu, Xiongfei Ai, Danyu Du, Nan Su et al. Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop Oncotarget 12/15/2017 [PMID: 29299159]
• Chain B, Arnold J, Akthar S, Brandt M, Davis D, Noursadeghi M, Lapp T, Ji C, Sankuratri S, Zhang Y, Govada L, Saridakis E, Chayen N A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody. PLoS ONE, 2015-06-01;10(6):e0128381. 2015-06-01 [PMID: 26030924] (ELISA Development, Human)
• James M. Fox, Richard Kasprowicz, Oliver Hartley, Nathalie Signoret CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells Journal of Leukocyte Biology 7/1/2015 [PMID: 25957306]
• Tilton J, Wilen C, Didigu C, Sinha R, Harrison J, Agrawal-Gamse C, Henning E, Bushman F, Martin J, Deeks S, Doms R A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol, 2010-08-11;84(20):10863-76. 2010-08-11 [PMID: 20702642]
• Mancino A, Schioppa T, Larghi P, Pasqualini F, Nebuloni M, Chen IH, Sozzani S, Austyn JM, Mantovani A, Sica A Divergent effects of hypoxia on dendritic cell functions. Blood, 2008-08-11;112(9):3723-34. 2008-08-11 [PMID: 18694997] (Flow Cytometry, Human)
• Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem., 1999-04-02;274(14):9617-26. 1999-04-02 [PMID: 10092648] (Flow Cytometry, Western Blot, Human)

Review for CCR5 Antibody (MAB1802) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer Flow Human 02/10/2015

Summary

• Application: Flow Cytometry
• Sample Tested: See PMID 22811524
• Species: Human

Bioinformatics

• Gene Symbol: CCR5